Evotec
Matthias Renz has extensive experience in business development and project management within the pharmaceutical industry. Currently serving as Vice President of Global Business Development at Evotec since October 2021, Renz previously held senior roles at Bayer from January 2012 to October 2021, including Senior Director of Business Development & Licensing in Oncology and Director of Business Development & Licensing for Specialty Medicine. Renz's career at Bayer Schering Pharma included the position of Senior International Project Manager from October 2007 to August 2010, and earlier roles at Schering encompassed Head of Early Formulation Development, International Project Coordinator, and Senior Scientist Group Lead from July 1999 to July 2007.
This person is not in the org chart
This person is not in any offices
Evotec
5 followers
Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners' target through a range of commercial structures, including research fees, milestones and/or royalties. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The Company seeks to partner these into collaborations in return for upfront payments, ongoing research payments. It consists of all partnerships derived from its internally developed assets and platforms and its participations in certain companies. It includes clinical initiations and progress of clinical pipeline within partnerships; expansion of academic BRIDGE network; research and development (R&D) progress with CureX/Target X initiatives, and focuses on induced pluripotent stem cells (iPSC) platform.